Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

Just weeks af­ter Mer­ck’s star check­point in­hibitor Keytru­da se­cured FDA ap­proval for a sub­set of blad­der can­cer pa­tients, Swiss com­peti­tor Roche’s Tecen­triq has failed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.